MedCity News February 26, 2025
Kathy Spencer-Pike

From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out

Somewhere in a laboratory, tucked away in its vessel, a small vial sits. However, this vial is special because it is emitting energy – potentially life-saving energy that is disappearing with every fleeting moment. This is not a scene from a thriller – it is the daily reality of radiopharmaceutical manufacturing, where life-saving cancer therapies are manufactured, tested, delivered, and administered while racing against the clock. From the executive boardrooms of pharma companies to academic research centers,...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Eli Lilly to invest $27B in manufacturing
Follow the Money: 3D Spatial Biology, AI-Powered Imaging Biomarkers, More
AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch
AI accelerates discovery of neurodevelopmental disorder-associated genes
Eikon raises $351M in one of the year’s largest biotech venture rounds

Share This Article